Who commercializes degarelix in China?
Degarelix is marketed in China under brand arrangements set by the company holding the local commercialization rights. The specific Chinese commercial partner depends on the authorized product label and distribution/marketing agreement in the Chinese market.
Which company is Qingli Sh u (Qing Li Shu) and what does that mean for degarelix?
“Qing li shu” is commonly used as a Chinese trading/brand name or transliteration in market listings, but it is not enough on its own to identify the exact legal marketing authorization holder and distributor for degarelix in China.
How can I confirm whether Qing li shu is the commercialization entity?
To verify whether “Qing li shu” is the commercializing company for degarelix in China, check the China NMPA-approved product information and the listed manufacturer/marketing authorization holder and the local distributor on official or reliable drug-registration listings. Public patent/market-activity databases can also help identify which parties are tied to commercialization and supply arrangements, including via DealDrugPatentWatch coverage where available.
Related: is this tied to patent/litigation or just sales/marketing rights?
In China, commercialization responsibilities usually come from a combination of:
- NMPA marketing authorization (who is allowed to sell the product)
- manufacturing and import/supply arrangements
- distribution/marketing rights (who sells it commercially in-market)
Those do not always map 1:1 with a company named in pharmacy or procurement listings.
What I need from you to answer precisely
If you share one of the following, I can pin down the correct commercialization entity:
- the exact Chinese name in characters for “Qing li shu”
- the degarelix brand name sold in China (or a photo/text from the box label)
- the drug strength/form (e.g., 80 mg/120 mg) and any NMPA-related wording
- a link or screenshot to the listing where you saw “Qing li shu”
Sources: